---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-013586"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:26:11.856824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M

## Summary
- Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).
- FDA cleared 510(k) for Tablo home use; shipments resumed after voluntary hold.
- FY 2022 guidance: revenue $105M-$110M (2-7% growth) citing staffing & inflation pressures.
- Gross margin improved to 15.1% from 4.2% YoY, but operating expenses rose to $47.5M vs $31.0M.
- Cash $295.4M as of June 30; non-GAAP net loss per share ($0.77).

## SEC filing metadata
- accession: 0000950170-22-013586
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/0000950170-22-013586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/om-20220801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-013586
- JSON: https://secwatch.observer/filing/0000950170-22-013586.json
- Plain text: https://secwatch.observer/filing/0000950170-22-013586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.